Dayvigo (Lemborexant) Cost in North Dakota 2026: Prices, Insurance & Savings

What Dayvigo Actually Costs in North Dakota Right Now

The sticker price and the price you pay are rarely the same number. Eisai, the manufacturer of Dayvigo (lemborexant), sets a wholesale acquisition cost (WAC) of approximately $320 per month for a 30-tablet supply at either the 5 mg or 10 mg strength [1]. That figure represents the list price before any rebates, discounts, or insurance adjudication.

Across North Dakota retail pharmacies in 2026, the average cash-pay price for Dayvigo sits near $85 per month. This gap between WAC and point-of-sale pricing reflects negotiated discounts, pharmacy benefit manager (PBM) contracts, and competitive market dynamics in the state. Prices vary by pharmacy. A Bismarck Walmart may charge differently than a Fargo independent. Patients paying out of pocket should compare at least three pharmacies and check discount aggregator platforms before filling.

The American Academy of Sleep Medicine (AASM) clinical practice guideline on pharmacologic treatment of chronic insomnia (2023) conditionally recommends DORAs including lemborexant as a treatment option for adults with sleep-onset and sleep-maintenance insomnia [2]. That guideline endorsement means most insurers have a reimbursement pathway, though formulary placement and tier assignment vary by plan.

North Dakota Medicaid Does Not Cover Dayvigo

North Dakota Medicaid does not include Dayvigo on its preferred drug list as of 2026. Patients enrolled in ND Medicaid who need a DORA-class medication face a coverage gap for this specific drug. The state formulary generally favors older, less expensive insomnia treatments such as generic zolpidem and trazodone before allowing access to newer branded agents [3].

There is no standard exception pathway published by North Dakota Medicaid specifically for Dayvigo. Prescribers can submit a prior authorization request documenting failure of or contraindication to preferred agents. Approval is not guaranteed. A 2021 analysis published in the Journal of Managed Care & Specialty Pharmacy found that state Medicaid programs covering DORAs typically required documented failure of at least two formulary-preferred agents before granting access [4].

For ND Medicaid enrollees, practical alternatives include generic suvorexant (the other FDA-approved DORA, whose patent situation may allow generic entry depending on litigation outcomes), generic zolpidem extended-release, or low-dose doxepin 3 mg or 6 mg (Silenor), which received FDA approval specifically for sleep-maintenance insomnia [5].

Commercial Insurance Coverage for Dayvigo in North Dakota

Most major commercial plans available in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica, do include Dayvigo on their formularies. Placement is typically Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with prior authorization required in the majority of cases.

Prior authorization criteria generally follow a step-therapy protocol. The insurer requires documentation that the patient has tried and failed (or has a documented contraindication to) at least one generic sleep agent. Some plans require failure of two agents. Once prior authorization is approved, copays for Tier 3 placement range from $35 to $75 per month depending on the specific plan design.

In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg both showed statistically significant improvements in sleep-onset latency and wake-after-sleep-onset compared to placebo at one month, with the 10 mg dose also demonstrating superiority over zolpidem extended-release 6.25 mg on wake-after-sleep-onset [6]. These efficacy data form the clinical rationale most prescribers use when submitting prior authorization appeals.

The FDA prescribing information for Dayvigo states: "DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance" [1]. That broad indication, covering both sleep-onset and sleep-maintenance subtypes, strengthens the prior authorization argument for patients who have partial response to agents that target only one domain.

How the Eisai Copay Savings Card Works in North Dakota

Eisai offers a copay savings program for Dayvigo that can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. The card is not available to patients covered by Medicare, Medicaid, TRICARE, or other federal or state government insurance programs.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Dayvigo, must reside in a state where the program operates (North Dakota is included), and must not be enrolled in any government-funded plan. The savings card covers the difference between the patient's copay and $0, up to a maximum annual benefit that Eisai sets (typically around $3,600 per year, though exact caps can change).

Patients activate the card through the Eisai patient support website or by calling the number on the card provided by their prescriber. The card integrates at the pharmacy point of sale. No mail-order workaround is needed. North Dakota pharmacies process the card as a secondary payer after the primary insurance adjudicates.

For uninsured patients, Eisai also maintains a patient assistance program (PAP) that provides Dayvigo at no cost to qualifying individuals whose household income falls below 400% of the federal poverty level. Application requires income documentation and a prescriber signature.

Compounded Lemborexant in North Dakota: Legal Status and Pricing

Compounded lemborexant is available in North Dakota through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on a valid patient-specific prescription from a licensed prescriber [7].

North Dakota Board of Pharmacy regulations allow 503A compounding as long as the pharmacy holds a valid ND compounding license and the prescriber provides an individualized prescription. The compound must be prepared in response to an individual patient order, not produced in bulk anticipation of orders (bulk compounding falls under 503B outsourcing facility rules).

Pricing for compounded lemborexant varies. Some 503A pharmacies offer it at significantly reduced cost compared to brand Dayvigo. Others may charge comparable prices depending on their sourcing costs for active pharmaceutical ingredient (API) and their compounding fees. Patients considering compounded lemborexant should verify that the compounding pharmacy sources its API from an FDA-registered supplier and follows United States Pharmacopeia (USP) chapter 795 standards for non-sterile compounding [8].

One consideration specific to compounded formulations: bioequivalence is not guaranteed. The FDA-approved Dayvigo tablet underwent rigorous pharmacokinetic testing in the SUNRISE trial program. A compounded capsule or tablet has not undergone that same level of regulatory scrutiny for dissolution rate or bioavailability. The clinical significance of this difference for an oral, immediate-release sleep agent is likely modest, but patients should discuss this with their prescriber.

Telehealth Prescribing of Dayvigo in North Dakota

North Dakota permits telehealth prescribing of Dayvigo. The state's telehealth parity law (N.D.C.C. 26.1-36-09.15) requires insurers to cover telehealth-delivered services on the same basis as in-person visits, which includes evaluation and management visits for insomnia and the prescribing of Schedule IV controlled substances like lemborexant.

Dayvigo is classified as Schedule IV under the Controlled Substances Act. The DEA's post-pandemic telehealth prescribing rules allow initial prescriptions for Schedule III-V substances via audio-video telehealth without a prior in-person exam, provided the prescriber holds a valid DEA registration and the patient interaction meets standard-of-care requirements [9].

HealthRX and similar telehealth platforms can evaluate patients in North Dakota for insomnia, prescribe Dayvigo when clinically appropriate, and transmit the prescription electronically to an ND retail pharmacy. Patients do not need to visit a brick-and-mortar clinic to obtain a Dayvigo prescription.

The AASM position statement on telehealth (2020) endorsed virtual evaluation for common sleep disorders including chronic insomnia, stating that "telehealth can effectively be used for the diagnosis and management of sleep disorders when in-person evaluation is not feasible or accessible" [10]. North Dakota's rural geography, where many residents live hours from a sleep specialist, makes telehealth access particularly relevant.

Cost Comparison: Dayvigo vs. Other Insomnia Drugs in North Dakota

Understanding where Dayvigo falls on the pricing spectrum helps patients and prescribers make informed formulary decisions. Generic zolpidem (immediate-release, 5 mg or 10 mg) costs approximately $4 to $10 per month at most North Dakota pharmacies. Generic zolpidem extended-release runs $15 to $30. Generic suvorexant pricing, if and when available, is expected to fall between $30 and $60 per month [3].

Low-dose doxepin (Silenor, now available as generic doxepin 3 mg and 6 mg) costs approximately $15 to $40 per month. Trazodone 50 mg, used off-label for insomnia, runs under $10 per month at most pharmacies [3].

Dayvigo at $85 cash-pay or $0 to $75 with insurance sits in the mid-to-upper range. The clinical question is whether its mechanism of action justifies the premium. A meta-analysis published in The Lancet (2022) examining 154 randomized controlled trials of insomnia pharmacotherapy found that DORAs as a class demonstrated favorable efficacy-to-side-effect profiles compared to benzodiazepine receptor agonists, with lower rates of next-day residual sedation and rebound insomnia on discontinuation [11].

In SUNRISE-2 (N=949), lemborexant 5 mg and 10 mg maintained efficacy on subjective sleep-onset latency and sleep efficiency through 12 months of nightly use, with no evidence of tolerance development [12]. Dr. Margaret Moline, then of Eisai's neurology division, noted in the publication: "Sustained efficacy over 12 months without dose escalation differentiates lemborexant from older hypnotics that often require dose increases over time." That durability profile may justify the higher cost for patients who need long-term pharmacotherapy.

Strategies to Lower Your Dayvigo Cost in North Dakota

Start with the Eisai copay card if you have commercial insurance. That single step can eliminate your copay entirely. If you are uninsured, apply for the Eisai patient assistance program before paying cash.

If neither option applies, compare cash prices across North Dakota pharmacies using GoodRx, RxSaver, or similar discount platforms. Prices for the same drug at the same dose can vary by $50 or more between two pharmacies in the same city. Independent pharmacies sometimes offer lower cash prices than chain retailers.

Ask your prescriber about the 5 mg dose. Both strengths carry the same list price per tablet, so there is no cost advantage to dose splitting. But the FDA label recommends starting at 5 mg and increasing to 10 mg only if needed [1]. Patients who respond adequately to 5 mg avoid the conversation about dose escalation entirely.

For patients who cannot access Dayvigo at an affordable price, the AASM guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, noting that "CBT-I is effective, durable, and should be offered before or alongside pharmacotherapy" [2]. Several North Dakota providers and telehealth platforms offer structured CBT-I programs, which carry no ongoing medication cost.